Research moves forward: the main retatrutide trial is published
What changed
The TRIUMPH-1 trial was published in the New England Journal of Medicine: 2,339 adults with obesity and without diabetes, followed for 80 weeks. At the highest dose, average weight loss was 25.0%, compared with 3.9% on placebo. Retatrutide acts on three receptors (GLP-1, GIP and glucagon) and is given once a week.
What it means for you
- 1Retatrutide is not approved in any country. In the US, the maker gives early access only to a small number of patients who meet strict medical criteria, through their doctors. Products sold online as “retatrutide” are not approved medicines, and nobody can check what is in them.
- 2Good results come from the treatment you follow now, not the one you are waiting for. Questions about new options go to your doctor.
What the study does not show
The trial was funded by the maker and lasted 80 weeks. It did not compare retatrutide with Mounjaro or Wegovy and says nothing about people already on another treatment. In another trial from the same programme, 13.5% of participants on the highest dose stopped treatment because of side effects, compared with 4.8% on placebo.
What does not change
The approved medicines and their leaflets stay the same.
Sources
- New England Journal of Medicine, 29 September 2026 (Jastreboff et al., TRIUMPH-1) — reported by Scientific Americanscientificamerican.com · accessed 15 Nov
- Eli Lilly — TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026investor.lilly.com · accessed 15 Nov
- Reuters via FOX 9 — Eli Lilly offers retatrutide to some patients before FDA approval, 7 August 2026fox9.com · accessed 16 Nov